10 likes | 183 Views
Pre-treatment. Post-treatment. II. I. Pt #1. EGFR-del19. EGFR-del19-T790M. (Nuclear β -catenin 21.8%). (51.3 %). III. IV. Pt # 2. EGFR-L858R. EGFR-L858R-T790M. (4.0%). (20.7%). V. VI. Pt # 3. EGFR-del19. EGFR-del19-T790M. (3.8 %). (34.4%). VII. VIII. Pt # 4. EGFR-L858R.
E N D
Pre-treatment Post-treatment II I Pt #1 EGFR-del19 EGFR-del19-T790M • (Nuclearβ-catenin21.8%) (51.3%) III IV Pt # 2 EGFR-L858R EGFR-L858R-T790M • (4.0%) (20.7%) V VI Pt # 3 EGFR-del19 EGFR-del19-T790M (3.8%) (34.4%) VII VIII Pt # 4 EGFR-L858R EGFR-L858R-T790M (35.0%) (38.9%) Supplementary Figure S2. Expression of β-catenin in pre- and post-EGFR TKIs lung biopsies.